Larisa J Geskin

Title: Larisa J Geskin: Innovator in Cutaneous T-Cell Lymphoma Research

Introduction

Larisa J Geskin is a prominent inventor based in Riverdale, NY (US), known for her significant contributions to the field of dermatology, particularly in the diagnosis and treatment of cutaneous T-cell lymphoma (CTCL). With a total of five patents to her name, her work has advanced the understanding of biomarkers associated with this complex disease.

Latest Patents

Among her latest patents is a groundbreaking method for the diagnosis, prognosis, and determination of treatment for cutaneous T-cell lymphoma. This invention focuses on biomarkers such as TOX, PLS3, KIR3DL2, GATA3, and RUNX3. The research indicates that increased expression of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL, while decreased expression of RUNX3 is also linked to the disease. These biomarkers can be utilized to diagnose CTCL and to design and monitor treatment strategies effectively.

Career Highlights

Larisa J Geskin is affiliated with the University of Pittsburgh, where she continues her research and innovation in the medical field. Her work has not only contributed to academic knowledge but has also had practical implications for patient care in oncology.

Collaborations

Some of her notable collaborators include Louis D Falo, Jr and Brittany Lynn O'Neill Dulmage, who have worked alongside her in various research initiatives.

Conclusion

Larisa J Geskin's innovative work in the field of cutaneous T-cell lymphoma exemplifies the impact of research on medical advancements. Her contributions through patents and collaborations continue to shape the future of diagnosis and treatment in dermatology.